Drug Profile
AIC 499
Alternative Names: AIC-499Latest Information Update: 12 Oct 2023
Price :
$50
*
At a glance
- Originator AiCuris; Ligand Pharmaceuticals
- Class Antibacterials; Beta-lactams
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 12 Oct 2023 Discontinued - Phase-I for Gram-negative infections (In volunteers) in Austria (IV) (AiCuris pipeline, October 2023)
- 12 Oct 2023 Discontinued - Preclinical for Gram-negative infections in Germany, USA (IV) (AiCuris pipeline, October 2023)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Austria (IV)